Cyclic nucleotide phosphodiesterase 4 (PDE4)

Cyclic nucleotide phosphodiesterase 4 (PDE4) is a family of enzymes that catalyze the hydrolysis of cyclic adenosine monophosphate (cAMP) to inactive 5’-AMP, thereby regulating intracellular cAMP levels and modulating cAMP-dependent signaling pathways. The PDE4 family includes four genes (PDE4A-D), each producing multiple isoforms with distinct regulatory and targeting sequences, enabling the fine-tuning of spatially confined cAMP pools in different cellular compartments. PDE4 isoforms are particularly abundant in immune, inflammatory, and neuronal cells, playing essential roles in the regulation of inflammatory responses, neuronal signaling, cardiac function, and more. Inhibition of PDE4 elevates intracellular cAMP, leading to broad anti-inflammatory effects, which has led to the development of several clinically approved drugs for diseases like COPD, psoriasis, and inflammatory disorders. The structural diversity of PDE4 forms, with unique dimerization properties and regulatory upstream conserved regions (UCRs), allows for complex modulation and drug targeting, making PDE4 a validated therapeutic target for multiple disease indications. Major challenges include systemic side effects due to broad cAMP modulation, requiring the development of isoform-selective inhibitors or localized drug delivery.

Other names

cAMP-specific phosphodiesterase 4PDE4APDE4BPDE4CPDE4D

Competitive inhibition of cAMP hydrolysis (PDE4 inhibitors block the catalytic domain, elevating intracellular cAMP); Disruption of compartmentalized cAMP signaling by blocking enzyme activity